Cetera Investment Advisers Increases Holdings in Healthpeak Properties, Inc. $DOC

Cetera Investment Advisers lifted its stake in shares of Healthpeak Properties, Inc. (NYSE:DOC) by 16.3% during the first quarter, HoldingsChannel.com reports. The firm owned 506,049 shares of the real estate investment trust’s stock after purchasing an additional 70,929 shares during the quarter. Cetera Investment Advisers’ holdings in Healthpeak Properties were worth $8,314,000 as of its most recent filing with the SEC.

Other institutional investors have also added to or reduced their stakes in the company. Norges Bank bought a new stake in shares of Healthpeak Properties during the fourth quarter valued at about $153,550,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Healthpeak Properties by 694.6% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 8,016,692 shares of the real estate investment trust’s stock valued at $153,520,000 after acquiring an additional 7,007,777 shares during the period. Bank of New York Mellon Corp boosted its position in shares of Healthpeak Properties by 60.3% in the first quarter. Bank of New York Mellon Corp now owns 15,456,420 shares of the real estate investment trust’s stock valued at $253,949,000 after acquiring an additional 5,815,189 shares during the period. Fuller & Thaler Asset Management Inc. grew its stake in Healthpeak Properties by 19.2% during the fourth quarter. Fuller & Thaler Asset Management Inc. now owns 29,648,260 shares of the real estate investment trust’s stock valued at $476,744,000 after acquiring an additional 4,776,056 shares in the last quarter. Finally, Millennium Management LLC grew its stake in Healthpeak Properties by 235.3% during the fourth quarter. Millennium Management LLC now owns 3,512,223 shares of the real estate investment trust’s stock valued at $56,477,000 after acquiring an additional 2,464,612 shares in the last quarter. Hedge funds and other institutional investors own 93.57% of the company’s stock.

Insider Activity at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of the firm’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the transaction, the insider directly owned 7,636 shares of the company’s stock, valued at approximately $148,520.20. This trade represents a 59.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.23% of the company’s stock.

Healthpeak Properties Stock Down 1.1%

Shares of NYSE:DOC opened at $21.83 on Friday. Healthpeak Properties, Inc. has a 52-week low of $15.70 and a 52-week high of $22.95. The firm has a fifty day moving average of $21.01 and a 200 day moving average of $18.65. The firm has a market capitalization of $15.05 billion, a PE ratio of 68.21, a price-to-earnings-growth ratio of 3.43 and a beta of 1.02. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.96 and a current ratio of 2.96.

Healthpeak Properties (NYSE:DOC) last released its earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.02. Healthpeak Properties had a return on equity of 2.61% and a net margin of 7.73%.The business had revenue of $752.95 million for the quarter, compared to analysts’ expectations of $694.59 million. During the same quarter in the prior year, the firm earned $0.46 earnings per share. The firm’s revenue was up 7.1% on a year-over-year basis. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, research analysts anticipate that Healthpeak Properties, Inc. will post 1.75 EPS for the current fiscal year.

Healthpeak Properties Announces Dividend

The company also recently disclosed a monthly dividend, which will be paid on Friday, September 25th. Stockholders of record on Monday, September 14th will be given a dividend of $0.1017 per share. The ex-dividend date is Monday, September 14th. This represents a c) annualized dividend and a dividend yield of 5.6%. Healthpeak Properties’s dividend payout ratio is 381.25%.

Analyst Upgrades and Downgrades

DOC has been the topic of several recent analyst reports. Evercore cut shares of Healthpeak Properties from an “outperform” rating to an “in-line” rating and set a $21.00 target price on the stock. in a research note on Monday, May 11th. Mizuho increased their price objective on Healthpeak Properties from $21.00 to $24.00 and gave the stock an “outperform” rating in a research report on Monday, July 6th. Robert W. Baird lifted their price objective on Healthpeak Properties from $19.00 to $21.00 and gave the company an “outperform” rating in a research note on Wednesday, May 13th. Weiss Ratings upgraded Healthpeak Properties from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, May 8th. Finally, Raymond James Financial initiated coverage on Healthpeak Properties in a research report on Wednesday, June 17th. They set a “market perform” rating for the company. Four analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. Based on data from MarketBeat, Healthpeak Properties presently has a consensus rating of “Hold” and a consensus target price of $20.62.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.